Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
6.66
+0.16 (2.46%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Biodexa Pharmaceuticals Revenue
Biodexa Pharmaceuticals had revenue of 83.00K GBP in the twelve months ending June 30, 2024, down -84.31% year-over-year. In the year 2023, Biodexa Pharmaceuticals had annual revenue of 381.00K, down -45.49%.
Revenue (ttm)
83.00K GBP
Revenue Growth
-84.31%
P/S Ratio
11.83
Revenue / Employee
3,952 GBP
Employees
21
Market Cap
3.87M USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 381.00K | -318.00K | -45.49% |
Dec 31, 2022 | 699.00K | 121.00K | 20.93% |
Dec 31, 2021 | 578.00K | 235.00K | 68.51% |
Dec 31, 2020 | 343.00K | -331.00K | -49.11% |
Dec 31, 2019 | 674.00K | -1.26M | -65.22% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBDRX News
- 16 hours ago - Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 1 day ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out - Accesswire
- 2 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect - Accesswire
- 6 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out - Accesswire
- 7 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation - Accesswire
- 12 days ago - Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer - Accesswire
- 14 days ago - Biodexa Announces Successful Appeal of Nasdaq Delisting - GlobeNewsWire
- 25 days ago - Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma - GlobeNewsWire